...
机译:与Rivaroxaban的复发性卒中与阿司匹林相比,根据心房颤动的预测因子进行了患者的心房颤动的二级分析,随机临床试验
McMaster Univ Dept Med Populat Hlth Res Inst Div Cardiol Hamilton Hlth Sci Hamilton ON Canada;
Sunnybrook Hlth Sci Ctr Div Neurol &
Hurvitz Brain Sci Program Toronto ON Canada;
Hamilton Hlth Sci Populat Hlth Res Inst Hamilton ON Canada;
Univ Hosp Basel Dept Internal Med Basel Switzerland;
Bayer AG Wuppertal Germany;
Univ Penn Electrophysiol Sect Cardiovasc Div Cardiol Sect Philadelphia PA 19104 USA;
Univ Klinikum Wurzburg Dept Neurol Wurzburg Germany;
St Annes Univ Hosp Int Clin Res Ctr Neurol Dept Brno Czech Republic;
Sapienza Univ Rome Dept Human Neurosci Rome Italy;
Inst Nacl Neurol Neurocirug Mexico City DF Mexico;
Univ Thesally Dept Med Larisa Greece;
Univ Western Australia Sir Charles Gairdner Hosp UWA Med Sch Perth WA Australia;
McMaster Univ Populat Hlth Res Inst Dept Med Neurol Hamilton ON Canada;
Univ Alberta Dept Med Edmonton AB Canada;
VA Portland Hlth Care Syst OHSU Dept Neurol Portland OR USA;
Capital Med Univ Beijing Tiantan Hosp Beijing Peoples R China;
Int Univ Hlth &
Welf Sanno Hosp &
Sanno Med Ctr Tokyo Japan;
Charite Univ Med Berlin Klin Neurol Berlin Germany;
Univ Calgary Dept Clin Neurosci Radiol &
Community Hlth Sci Foothills Med Ctr Calgary AB Canada;
Inst Psychiat &
Neurol Dept Neurol Warsaw Poland;
Inst Psychiatiy &
Neurol Dept Neurol 2 Warsaw Poland;
Med Univ Warsaw Dept Pharmacol Warsaw Poland;
Ctr Hosp Neurol Dept Coimbra Portugal;
Bayer US LLC Pharmaceut Clin Dev Thrombosis Whippany NJ USA;
Hamilton Hlth Sci Populat Hlth Res Inst Hamilton ON Canada;
McMaster Univ Dept Med Populat Hlth Res Inst Div Cardiol Hamilton Hlth Sci Hamilton ON Canada;
机译:与Rivaroxaban的复发性卒中与阿司匹林相比,根据心房颤动的预测因子进行了患者的心房颤动的二级分析,随机临床试验
机译:根据风险状态的未确定源栓塞患者复发性缺血性脑卒中患者的预测因素及蓖麻毒素与阿司匹林的影响:导航esus试验
机译:非瓣膜性房颤患者停用利伐沙班与华法林相比的结果:ROCKET AF试验的分析(Rivaroxaban每日一次口服口服直接Xa抑制与维生素K拮抗作用相比较,以预防中风和房颤栓塞试验)
机译:永久性心房纤颤患者心率变异性的多尺度熵特征分析以预测缺血性中风风险
机译:阿哌沙班,达比加群,利伐沙班和华法林预防房颤预防中风的成本效益。
机译:利伐沙班或阿司匹林治疗卵圆孔未闭和栓塞性卒中的来源尚未确定:来自NAVIGATE ESUS试验的预先确定的亚组分析
机译:ROCKET AF试验对非瓣膜性房颤患者中止利伐沙班与华法林比较的结果(Rivaroxaban每日一次,口服,直接因子Xa抑制与维生素K拮抗剂的比较预防房颤的卒中和栓塞试验)